Skip to main content
Premium Trial:

Request an Annual Quote

Short Reads: Dec 1, 2001 (rev. 1)

Premium

Things fall apart at InforMax, or so it seems. CEO Alex Titomirov announced that he’ll step down but will remain chairman. James Bernstein, COO and president, is also leaving at the end of the year. Heidrick & Struggles has been retained to find a new CEO.

 

NCBI co-founder Mark Boguski was elected to the Institute of Medicine of the National Academy of Sciences. Previously the VP of genomics at Rosetta Inpharmatics, Boguski remains a consultant to the company.

 

James Fickett moved from GlaxoSmithKline to AstraZeneca, where he’s the new global director of bioinformatics and is based at the company’s R&D center near Boston.

 

It would appear that Richard Gill, new president and CEO of bioinformatics company AnVil Informatics, has never had a lesser position. He was previously prez and CEO of ActiveCyte, and before that president and COO of Genome Therapeutics.

 

Anyone who can honestly say he’s been the president of International Light wins our favor. Michael Olex, who was indeed head of the radiometer manufacturer, popped up as senior vice president of operations and manufacturing at US Genomics. He previously worked for a decade at PerSeptive Biosystems. Next move: CEO of World Peace.

Kevin Skol, formerly with Elan, joined Digital Gene Technologies as vice president of business development.

 

Phoenix, Ariz.’s Designer Genes hired David McCarthy from Oklahoma State University as its director of genomics and Seth Dobrin from Genometrix as director of product development.

 

After working at bioinformatics firm Xpogen, Jeff Livingstone went to Signet Laboratories, where he’s VP of biz development.

 

ViaLogy, a Pasadena, Calif.-based company working with detection sensitivity for biochips, appointed Douglas Lane as CEO. Lane has worked for Hyseq and Strata Biosciences, among others.

 

GeneProt hired Ranald Sutherland as its new vice president of business development. Sutherland, whose goal will be establishing partnerships with pharmas, previously worked for Hoffman-La Roche.

 

Wanderlust within:

Genset’s Daniel Cohen shed his old CSO title and is now director general of scientific strategy.

Allan Marchington, formerly general manager, was promoted to senior vice president of productivity.

Lion Bioscience announced that co-founder Reinhard Schneider will be its chief information officer.

J. Claiborne Stephens, previously executive director of population genomics at Genaissance Pharmaceuticals, moves up to vice president of genetics.

Geneticist Ranajit Chakraborty left the University of Texas Health Science Center and headed to the University of Cincinnati Medical Center, where he’ll do double duty as environmental health chair and director of the new UC Center for Genome Information.

 

Last seen at MWG Biotech, Peter Wolstenholme climbed aboard Stratagene as managing director for the company’s European operations.

 

Psychiatric Genomics of Gaithersburg, Md., hired David Theil as chief financial officer. Theil comes from telecommunications service provider The Signature Group, where he held the same position.

 

Indian bioinformatics company Strand Genomics announced that Seshadri Srinivasan, former CTO of network management at Lucent Technologies, came aboard as COO and acting CEO. Also, Sreenivas Devidas joins as VP of business development from McKinsey, where he was the senior biotech consultant.

 

Paradigm Genetics takes a healthy step in the direction of healthcare with recent appointments. Jin Sun Kim is the first vice president to lead the human healthcare group, and Ian Mehr is director of business development for human health.

 

Mats Bergstrvm heads to Pyrosequencing, where he’s the new European sales director. He had been at Applied Biosystems Europe, where he was head of the PCR and consumables business unit.

 

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.